Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 29;10(8):1216.
doi: 10.3390/vaccines10081216.

Adapting Simon's Two-Stage Design for Efficient Screening of Filovirus Vaccines in Non-Human Primates

Nancy A Niemuth  1 , Carol L Sabourin  1 , Lucy A Ward  2
Affiliations

Adapting Simon's Two-Stage Design for Efficient Screening of Filovirus Vaccines in Non-Human Primates

Nancy A Niemuth et al. Vaccines (Basel). .

Abstract

The cynomolgus monkey (Macaca fascicularis) non-human primate (NHP) is widely used for filovirus vaccine testing. To use limited BSL-4 resources efficiently and minimize NHP usage, Simon's two-stage design was adapted to screen candidate Ebola virus (EBOV) vaccines in up to six NHPs with two (optimal), three, or four NHPs in Stage 1. Using the optimal design, two NHPs were tested in Stage 1. If neither survived, the candidate was rejected. Otherwise, it was eligible for Stage 2 testing in four NHPs. Candidates advanced if four or more NHPs were protected over both stages. An 80% efficacious candidate vaccine had 88.5% probability of advancing, and a 40% efficacious candidate vaccine had 83% probability of rejection. Simon's two-stage design was used to screen 27 EBOV vaccine candidates in 43 candidate regimens that varied in dose, adjuvant, formulation, or schedule. Of the 30 candidate regimens tested using two NHPs in Stage 1, 15 were rejected, nine were withdrawn, and six were tested in Stage 2. All six tested in Stage 2 qualified to advance in the product development pipeline. Multiple regimens for the EBOV vaccines approved by the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) in 2019 were tested in this program. This approach may also prove useful for screening Sudan virus (SUDV) and Marburg virus (MARV) vaccine candidates.

Keywords: Ebola virus (EBOV); Marburg virus (MARV); Simon’s two-stage; Sudan virus (SUDV); vaccine screening.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest. The sponsor/funder of this work was involved in conceptualization, design of the study and analysis/interpretation.

Figures

Figure 1
Figure 1
Decision tree for optimal Simon’s two-stage testing of vaccine candidates.
See this image and copyright information in PMC

References

    1. Bell B.P., Damon I.K., Jernigan D.B., Kenyon T.A., Nichol S.T., O’Connor J.P., Tappero J.W. Overview, Control Strategies, and Lessons Learned in the CDC Response to the 2014–2016 Ebola Epidemic. MMWR Suppl. 2016;65((Suppl. 3)):4–11. doi: 10.15585/mmwr.su6503a2. - DOI - PubMed
    1. Food and Drug Administration. Center for Drug Evaluation and Research. Center for Biologics Evaluation and Research Guidance for Industry: Product Development Under the Animal Rule. [(accessed on 10 June 2022)];2015 October; Available online: https://www.fda.gov/regulatory-information/search-fda-guidance-documents....
    1. Gross L., Lhomme E., Pasin C., Richert L., Thiebaut R. Ebola vaccine development: Systematic review of pre-clinical and clinical studies, and meta-analysis of determinants of antibody response variability after vaccination. Int. J. Infect. Dis. 2018;74:83–96. doi: 10.1016/j.ijid.2018.06.022. - DOI - PubMed
    1. Niemuth N.A., Fallacara D., Triplett C.A., Tamrakar S.M., Rajbhandari A., Florence C., Ward L., Griffiths A., Carrion R., Jr., Goez-Gazi Y., et al. Natural history of disease in cynomolgus monkeys exposed to Ebola virus Kikwit strain demonstrates the reliability of this non-human primate model for Ebola virus disease. PLoS ONE. 2021;16:e0252874. doi: 10.1371/journal.pone.0252874. - DOI - PMC - PubMed
    1. Envigo How COVID-19 Has Affected the Non-Human Primate Shortage. Envigo. Indianapolis, IN, USA. Mar 16, 2022. [(accessed on 10 June 2022)]. Available online: https://blog.envigo.com/how-covid-19-has-affected-non-human-primate-shor....